CA
DFTX

CoreCap Advisors’s Definium Therapeutics DFTX Stock Holding History

CoreCap Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5
Closed -$95 – 3248
2026
Q1 		$95 Hold
5
– – ﹤0.01% 2840
2025
Q4 		$67 Hold
5
– – ﹤0.01% 2891
2025
Q3 		$59 Hold
5
– – ﹤0.01% 2748
2025
Q2 		$32 Hold
5
– – ﹤0.01% 2722
2025
Q1 		$29 Hold
5
– – ﹤0.01% 3101
2024
Q4 		$35 Sell
5
-10
-67% -$69 ﹤0.01% 2808
2024
Q3 		$85 Hold
15
– – ﹤0.01% 2563
2024
Q2 		$108 Hold
15
– – ﹤0.01% 1531
2024
Q1 		$141 Buy
+15
New +$86 ﹤0.01% 2429
2022
Q4 		$37 Buy
+17
New +$47 ﹤0.01% 2349
2022
Q3 		– Sell
-17
Closed – – 1472
2022
Q2 		$0 Buy
+17
New +$215 ﹤0.01% 2222

Other funds holding DFTX

PFA
Peak Financial Advisors Denver, Colorado $242M AUM 19.63% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
BRG
Bay Rivers Group Williamsburg, Virginia $293M AUM 48.17% 1-Year Est. Return
SCI
Stableford Capital II Scottsdale, Arizona $289M AUM 20.84% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
WPW
Waldron Private Wealth Bridgeville, Pennsylvania $2.89B AUM 23.18% 1-Year Est. Return

CoreCap Advisors's DFTX Position: Q2 2026 in Review

CoreCap Advisors sold out of Definium Therapeutics (DFTX) in Q2 2026, closing a stake of 5 shares — an estimated $95 sold.

CoreCap Advisors first reported a position in DFTX in Q2 2022 and held it in 11 quarters. The position peaked at $141 in Q1 2024. 20 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • CoreCap Advisors reported no remaining Definium Therapeutics position as of Q2 2026 after selling out during the quarter.
  • CoreCap Advisors sold 5 Definium Therapeutics shares in Q2 2026, an estimated $95.
  • CoreCap Advisors first reported a position in Definium Therapeutics in Q2 2022 and held it in 11 quarters.
  • CoreCap Advisors's Definium Therapeutics position peaked at $141 in Q1 2024.
  • 20 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.